Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2023 Oct 16;30(1):304. doi: 10.1038/s41591-023-02639-3

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Catherine J Mummery 1,✉, Anne Börjesson-Hanson 2, Daniel J Blackburn 3, Everard G B Vijverberg 4, Peter Paul De Deyn 5, Simon Ducharme 6, Michael Jonsson 7, Anja Schneider 8, Juha O Rinne 9, Albert C Ludolph 10, Ralf Bodenschatz 11, Holly Kordasiewicz 12,#, Eric E Swayze 12,#, Bethany Fitzsimmons 12,#, Laurence Mignon 12,#, Katrina M Moore 12,#, Chris Yun 12,#, Tiffany Baumann 12,#, Dan Li 12,#, Daniel A Norris 12,#, Rebecca Crean 12,#, Danielle L Graham 13,#, Ellen Huang 13,#, Elena Ratti 13,#, C Frank Bennett 12,#, Candice Junge 12, Roger M Lane 12
PMCID: PMC10803246  PMID: 37845513

Correction to: Nature Medicine 10.1038/s41591-023-02326-3. Published online 24 April 2023.

In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read “Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK” in the HTML and PDF versions of the article.

Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES